Crbn(I391V) is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice

Thalidomide and its derivatives, lenalidomide and pomalidomide, are clinically effective treatments for multiple myeloma and myelodysplastic syndrome with del(5q). These molecules lack activity in murine models, limiting investigation of their therapeutic activity or toxicity in vivo. Here, we repor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Fink, Emma C., McConkey, Marie, Adams, Dylan N., Haldar, Saurav D., Kennedy, James A., Guirguis, Andrew A., Udeshi, Namrata D., Mani, D. R., Chen, Michelle, Liddicoat, Brian, Svinkina, Tanya, Nguyen, Andrew T., Carr, Steven A., Ebert, Benjamin L.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6172563/
https://ncbi.nlm.nih.gov/pubmed/30064974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-05-852798
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados